204 related articles for article (PubMed ID: 27273130)
1. Prognostic significance of S100A4 expression in stage II and III colorectal cancer: results from a population-based series and a randomized phase III study on adjuvant chemotherapy.
Boye K; Jacob H; Frikstad KA; Nesland JM; Maelandsmo GM; Dahl O; Nesbakken A; Flatmark K
Cancer Med; 2016 Aug; 5(8):1840-9. PubMed ID: 27273130
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of S100A4-expression and subcellular localization in early-stage breast cancer.
Egeland EV; Boye K; Park D; Synnestvedt M; Sauer T; ; Naume B; Borgen E; Mælandsmo GM
Breast Cancer Res Treat; 2017 Feb; 162(1):127-137. PubMed ID: 28058579
[TBL] [Abstract][Full Text] [Related]
3. LGR5 and CD133 as prognostic and predictive markers for fluoropyrimidine-based adjuvant chemotherapy in colorectal cancer.
Stanisavljević L; Myklebust MP; Leh S; Dahl O
Acta Oncol; 2016 Dec; 55(12):1425-1433. PubMed ID: 27435662
[TBL] [Abstract][Full Text] [Related]
4. Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy.
Edler D; Glimelius B; Hallström M; Jakobsen A; Johnston PG; Magnusson I; Ragnhammar P; Blomgren H
J Clin Oncol; 2002 Apr; 20(7):1721-8. PubMed ID: 11919227
[TBL] [Abstract][Full Text] [Related]
5. Differential clinical benefits of 5-fluorouracil-based adjuvant chemotherapy for patients with stage III colorectal cancer according to CD133 expression status.
Shikina A; Shinto E; Hashiguchi Y; Ueno H; Naito Y; Okamoto K; Kubo T; Fukazawa S; Yamamoto J; Hase K
Jpn J Clin Oncol; 2014 Jan; 44(1):42-8. PubMed ID: 24244031
[TBL] [Abstract][Full Text] [Related]
6. Identification and Construction of Combinatory Cancer Hallmark-Based Gene Signature Sets to Predict Recurrence and Chemotherapy Benefit in Stage II Colorectal Cancer.
Gao S; Tibiche C; Zou J; Zaman N; Trifiro M; O'Connor-McCourt M; Wang E
JAMA Oncol; 2016 Jan; 2(1):37-45. PubMed ID: 26502222
[TBL] [Abstract][Full Text] [Related]
7. A systematic overview of chemotherapy effects in colorectal cancer.
Ragnhammar P; Hafström L; Nygren P; Glimelius B;
Acta Oncol; 2001; 40(2-3):282-308. PubMed ID: 11441937
[TBL] [Abstract][Full Text] [Related]
8. Mismatch repair protein expression is an independent prognostic factor in sporadic colorectal cancer.
Ohrling K; Edler D; Hallström M; Ragnhammar P
Acta Oncol; 2010 Aug; 49(6):797-804. PubMed ID: 20307245
[TBL] [Abstract][Full Text] [Related]
9. Expression of astrocyte-elevated gene-1 indicates prognostic value of fluoropyrimidine-based adjuvant chemotherapy in resectable stage III colorectal cancer.
Lin LW; Lai PS; Chen YY; Chen CY
Pathol Int; 2021 Nov; 71(11):752-764. PubMed ID: 34528330
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant regional chemotherapy and systemic chemotherapy versus systemic chemotherapy alone in patients with stage II-III colorectal cancer: a multicentre randomised controlled phase III trial.
Nordlinger B; Rougier P; Arnaud JP; Debois M; Wils J; Ollier JC; Grobost O; Lasser P; Wals J; Lacourt J; Seitz JF; Guimares dos Santos J; Bleiberg H; Mackiewickz R; Conroy T; Bouché O; Morin T; Baila L; van Cutsem E; Bedenne L
Lancet Oncol; 2005 Jul; 6(7):459-68. PubMed ID: 15992694
[TBL] [Abstract][Full Text] [Related]
11. Nuclear S100A4 is a novel prognostic marker in colorectal cancer.
Boye K; Nesland JM; Sandstad B; Mælandsmo GM; Flatmark K
Eur J Cancer; 2010 Nov; 46(16):2919-25. PubMed ID: 20719498
[TBL] [Abstract][Full Text] [Related]
12. Deleted in colorectal cancer protein expression as a possible predictor of response to adjuvant chemotherapy in colorectal cancer patients.
Gal R; Sadikov E; Sulkes J; Klein B; Koren R
Dis Colon Rectum; 2004 Jul; 47(7):1216-24. PubMed ID: 15148649
[TBL] [Abstract][Full Text] [Related]
13. Expression of protein S100A4 is a predictor of recurrence in colorectal cancer.
Kwak JM; Lee HJ; Kim SH; Kim HK; Mok YJ; Park YT; Choi JS; Moon HY
World J Gastroenterol; 2010 Aug; 16(31):3897-904. PubMed ID: 20712050
[TBL] [Abstract][Full Text] [Related]
14. Lysosomal acid phosphatase 2 is an unfavorable prognostic factor but is associated with better survival in stage II colorectal cancer patients receiving chemotherapy.
Lee YC; Su CY; Lin YF; Lin CM; Fang CY; Lin YK; Hsiao M; Chen CL
Oncotarget; 2017 Feb; 8(7):12120-12132. PubMed ID: 28076332
[TBL] [Abstract][Full Text] [Related]
15. Metastasis-associated protein S100A4 and p53 predict relapse in curatively resected stage III and IV (M0) gastric cancer.
Kim YJ; Kim MA; Im SA; Kim TM; Kim DW; Yang HK; Heo DS; Lee KU; Choe KJ; Kim NK; Kim TY; Kim WH; Bang YJ
Cancer Invest; 2008 Mar; 26(2):152-8. PubMed ID: 18259945
[TBL] [Abstract][Full Text] [Related]
16. EMMPRIN is associated with S100A4 and predicts patient outcome in colorectal cancer.
Boye K; Nesland JM; Sandstad B; Haugland Haugen M; Mælandsmo GM; Flatmark K
Br J Cancer; 2012 Aug; 107(4):667-74. PubMed ID: 22782346
[TBL] [Abstract][Full Text] [Related]
17. Expression of cyclin D1a and D1b as predictive factors for treatment response in colorectal cancer.
Myklebust MP; Li Z; Tran TH; Rui H; Knudsen ES; Elsaleh H; Fluge Ø; Vonen B; Myrvold HE; Leh S; Tveit KM; Pestell RG; Dahl O
Br J Cancer; 2012 Nov; 107(10):1684-91. PubMed ID: 23099809
[TBL] [Abstract][Full Text] [Related]
18. Expression of p21WAF1 in Astler-Coller stage B2 colorectal cancer is associated with survival benefit from 5FU-based adjuvant chemotherapy.
Sulzyc-Bielicka V; Domagala P; Urasinska E; Bielicki D; Safranow K; Domagala W
Virchows Arch; 2011 Apr; 458(4):431-8. PubMed ID: 21369800
[TBL] [Abstract][Full Text] [Related]
19. Podoplanin, α-smooth muscle actin or S100A4 expressing cancer-associated fibroblasts are associated with different prognosis in colorectal cancers.
Choi SY; Sung R; Lee SJ; Lee TG; Kim N; Yoon SM; Lee EJ; Chae HB; Youn SJ; Park SM
J Korean Med Sci; 2013 Sep; 28(9):1293-301. PubMed ID: 24015033
[TBL] [Abstract][Full Text] [Related]
20. Tumor dihydropyrimidine dehydrogenase in stage II and III colorectal cancer: low level expression is a beneficial marker in oral-adjuvant chemotherapy, but is also a predictor for poor prognosis in patients treated with curative surgery alone.
Tsuji T; Sawai T; Takeshita H; Nakagoe T; Hidaka S; Atsushi Nanashima ; Yamaguchi H; Yasutake T; Nagayasu T; Tagawa Y
Cancer Lett; 2004 Feb; 204(1):97-104. PubMed ID: 14744539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
